Protection against mild COVID-19 wanes within a few months, but prevention of severe outcomes lasts longer (except in immunocompromised persons).
In several recent studies across different locales and settings, investigators have addressed waning vaccine effectiveness (VE) over time against different SARS-CoV-2 variants of concern.
Ferdinands et al. calculated VE using CDC data from almost 900,000 adults treated for COVID-like illness in several U.S. hospitals, emergency departments, or urgent care centers between January 2021 and July 2022. During Omicron predominance, VE of mRNA vaccines against COVID-19–associated emergency department visits fell to 30% within the first 6 months, then below 15% after 1 year. VE against COVID-19–associated hospital admissions varied between 73% and 48% within 1 year after two-dose vaccination. A third (booster) dose increased VE against associated h…
Authors
DisclosuresGrant/Research SupportNational Institutes of Health
DisclosuresGrant/Research SupportNational Institutes of Health
DisclosuresEditorial BoardsConsilium Infectiorum by InfectoPharm, Infection
DisclosuresEditorial BoardsConsilium Infectiorum by InfectoPharm, Infection
DisclosuresConsultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi
Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.
RoyaltiesUpToDate
Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases
DisclosuresConsultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi
Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.
RoyaltiesUpToDate
Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases